Three new shares were issued in this batch, and 23 were registered on the science and innovation board and the gem
The CSRC issued 3 new shares in this batch, and 23 were registered on the science and innovation board and the gem. Main board: Biyi Co., Ltd., Yuehai feed, Lily Co., Ltd. Scientific innovation board: Junpu intelligence, silinjie, Huaqin technology, green Shentong, Rongchang biology, Heyuan biology, China catalyst, AsiaInfo security, kunhengshunwei, science and technology navigation. Gem: softcom power, Hengwei battery, wankaixincai, Han's CNC, Huashi technology, newtag, he's Ophthalmology, Hawthorne Huatong, China automobile test, Biao shares, West Point pharmaceutical, Zhongke Jiangnan and zhaoxun media. Among them, and metabiology are worthy of key tracking. Heyuan biology is a biotechnology company focusing on the field of gene therapy, focusing on providing gene therapy cro and cdmo services. With the two core technology clusters built based on the comprehensive technology platform, large-scale GMP production platform and comprehensive service capacity of gene therapy, the company has cooperated with more than 90 cdmo projects and more than 50 cdmo projects under implementation, covering the pre ind and post ind stages of various gene therapy vectors, oncolytic viruses, car-t and other gene drugs. With milestone products such as kymriah and luxturna approved by FDA for listing, gene therapy continues to make breakthrough progress and become one of the Global Frontier pharmaceutical fields with the most development potential. Driven by the successive introduction of favorable industrial policies, the continuous injection of industrial capital and the expected approval and listing of gene therapy products, gene therapy technology will develop from conceptual stage to clinical and industrialization in the future, and the market scale will expand rapidly. Under the trend of accelerating the clinical and marketing process of gene therapy, the high cost and high risk of gene drug research and development will drive the rapid development of gene therapy cdmo industry. As a leading cdmo service provider of gene therapy, the company will fully benefit from the development dividend of the industry.
In this period, there will be 25 on the scientific innovation board and gem and 7 on the main board
In this period, there were 25 meetings on the scientific innovation board and gem, an increase over the previous period, and the passing rate was 92%. There are 7 meetings on the main board, an increase over the previous two, and the passing rate is 100%. Excluding financial stocks, the average fund-raising of the science and innovation board and the gem in this period was about 933 million yuan, lower than the 1.691 billion yuan in the previous period. The average fund-raising of the main board in this period is about 713 million yuan, higher than 563 million yuan in the previous period. In this period, 8 new shares were listed on the science and innovation board, with an average increase of 16.1% on the first day of listing, higher than 1.9% in the previous period. A total of 13 new shares were listed on the gem in this period, with an average increase of 58.9% on the first day of listing, higher than 50.5% in the previous period. In terms of the increase in the opening of new shares, there were 5 new shares on the main board in the current period, with an average opening increase of 174%, higher than 98% in the previous period.
Key tracking combination of open source small and medium cap new shares
Ligao Foods Co.Ltd(300973) (a leading enterprise in frozen and baked food, the industry is in a period of rapid growth and the concentration is still low), Xiangyumedicalco.Ltd(688626) (the leader of domestic rehabilitation medical devices, which can produce a full range of rehabilitation medical devices, and is expected to continue to benefit from the release of the demand of China's health market and the trend of import substitution) Zhejiang Huakang Pharmaceutical Co.Ltd(605077) (xylitol production ranks first in China and second in the world, functional sugar alcohols are low in calories and do not cause dental caries, which is expected to continuously replace sugar), Marssenger Kitchenware Co.Ltd(300894) (leading enterprise of high-end integrated stoves, with broad industry penetration space), Pylon Technologies Co.Ltd(688063) (the world's leading supplier of energy storage battery system, fully benefiting from the development of renewable energy industry) Shanghai Titan Scientific Co.Ltd(688133) (comprehensive scientific research service provider, rapid expansion of platform), Shanghai Aladdin Biochemical Technology Co.Ltd(688179) (high-end scientific research reagent R & D provider, with broad domestic substitution space).
Risk tips: macroeconomic risks and changes in IPO system.
